Dihydrofolate Reductase
Introduction
Section titled “Introduction”Dihydrofolate reductase (DHFR) is a crucial enzyme involved in the folate metabolic pathway, essential for all forms of life. It catalyzes the reduction of dihydrofolate to tetrahydrofolate, a vital coenzyme required for the synthesis of purines, pyrimidines, and certain amino acids. These molecules are fundamental building blocks for DNA, RNA, and proteins, making DHFR activity indispensable for cell growth, division, and repair.
Biological Basis
Section titled “Biological Basis”The primary biological function of DHFR is to regenerate tetrahydrofolate from dihydrofolate, which is produced during the conversion of deoxyuridylate to deoxythymidylate, a key step in DNA synthesis. By maintaining a steady supply of tetrahydrofolate, DHFRensures the continuous production of nucleotides necessary for DNA replication and repair. This role highlights its importance in rapidly dividing cells, such as those found in bone marrow, the gastrointestinal tract, and cancerous tumors.
Clinical Relevance
Section titled “Clinical Relevance”Due to its critical role in nucleotide synthesis and cell proliferation,DHFR has long been a significant target for various therapeutic agents. Drugs that inhibit DHFR, known as antifolates, are widely used in medicine. Methotrexate, a potent DHFRinhibitor, is a cornerstone of chemotherapy for various cancers, including leukemia, lymphoma, and breast cancer, by blocking DNA synthesis in rapidly dividing cancer cells. It is also used in the treatment of autoimmune diseases like rheumatoid arthritis and psoriasis for its immunosuppressive effects. Additionally, antibacterial agents like trimethoprim and antimalarial drugs like pyrimethamine target bacterial and parasiticDHFR enzymes, respectively, exploiting differences between human and microbial enzymes to achieve selective toxicity. Genetic variations (SNPs) in the DHFR gene can influence enzyme activity, stability, or expression, potentially affecting an individual’s response to antifolate therapies, including drug efficacy and the incidence of side effects.
Social Importance
Section titled “Social Importance”The understanding of DHFR’s function and its inhibition has profoundly impacted public health. The development of antifolate drugs has provided life-saving treatments for millions battling cancer and debilitating autoimmune conditions. Research intoDHFR continues to drive advancements in personalized medicine, aiming to tailor drug dosages and choices based on an individual’s genetic makeup to optimize treatment outcomes and minimize adverse reactions. Furthermore, studies on DHFR from various pathogens contribute to the ongoing development of new antimicrobial and antiparasitic agents, addressing global health challenges such as antibiotic resistance and infectious diseases.
Limitations
Section titled “Limitations”Methodological and Statistical Considerations
Section titled “Methodological and Statistical Considerations”The interpretation of genetic associations is subject to several methodological and statistical constraints. Moderate cohort sizes can limit statistical power, increasing the risk of false negative findings for associations of modest effect. Conversely, the extensive number of statistical tests performed in genome-wide association studies (GWAS) heightens the potential for false positive findings, particularly if not confirmed through rigorous replication efforts . The rs216311 variant, an intronic single nucleotide polymorphism inVWF, may influence the gene’s expression or the stability of its mRNA, potentially altering VWF levels or function, which in turn impacts an individual’s susceptibility to bleeding disorders or thrombotic risks. [1] While VWF’s primary role is in blood coagulation, its broader impact on vascular health means that conditions affecting blood components can indirectly relate to DHFR, which is vital for folate metabolism and the production of healthy blood cells.
The ABO gene determines the ABO blood group antigens expressed on red blood cells and other cell types, influencing numerous physiological traits beyond simple blood typing. Variants such as rs9411377 and rs676457 are located within the ABO locus and are strongly associated with an individual’s specific blood group, which in turn affects plasma VWF levels; individuals with blood group O typically exhibit lower VWF concentrations compared to non-O individuals. [1] This impact on VWF levels means ABOvariants can modulate an individual’s risk for various conditions, including venous thromboembolism and arterial diseases. Although there is no direct metabolic pathway linkingABO to DHFR, the influence of blood group on overall cardiovascular health and disease susceptibility, often studied in large population cohorts, suggests an indirect connection through the complex interplay of genetic factors and metabolic processes thatDHFR facilitates. [1]
The rs1065853 variant is situated in the intergenic region between the APOE and APOC1 genes, a cluster critical for lipid metabolism. APOEplays a central role in the transport and receptor-mediated uptake of lipids, particularly triglyceride-rich lipoproteins, whileAPOC1 modulates APOEfunction and lipid exchange processes. This variant is recognized for its association with varying lipid levels, including total cholesterol and triglycerides, which are significant risk factors for coronary heart disease.[1] The modulation of lipid profiles by rs1065853 can therefore substantially influence an individual’s predisposition to cardiovascular diseases. The relevance toDHFRstems from their convergent roles in cardiovascular health;DHFRis essential for folate metabolism, which helps regulate homocysteine levels, a known independent risk factor for cardiovascular disease. Genetic variations affecting lipid metabolism, such asrs1065853 , can interact with the effects of folate status and DHFRactivity, collectively shaping an individual’s overall cardiovascular risk profile, as investigated in broad genetic studies across European populations.[1]
The provided research context does not contain information regarding the management, treatment, or prevention of ‘dihydrofolate reductase’. Therefore, based on the given instructions, no content can be generated for this section.
Key Variants
Section titled “Key Variants”| RS ID | Gene | Related Traits |
|---|---|---|
| rs216311 | VWF | blood protein amount platelet volume dihydrofolate reductase measurement platelet count level of dihydrofolate reductase in blood serum |
| rs9411377 rs676457 | ABO | folic acid amount platelet count factor VIII measurement C-C motif chemokine 14 measurement level of UL16-binding protein 2 in blood |
| rs1065853 | APOE - APOC1 | low density lipoprotein cholesterol measurement total cholesterol measurement free cholesterol measurement, low density lipoprotein cholesterol measurement protein measurement mitochondrial DNA measurement |
References
Section titled “References”[1] Aulchenko, Y. S., et al. “Loci influencing lipid levels and coronary heart disease risk in 16 European population cohorts.”Nature Genetics, vol. 41, no. 1, Jan. 2009, pp. 47-55.